These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
812 related articles for article (PubMed ID: 26632531)
1. Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations. Tada H; Kawashiri MA; Yoshida T; Teramoto R; Nohara A; Konno T; Inazu A; Mabuchi H; Yamagishi M; Hayashi K Circ J; 2016; 80(2):512-8. PubMed ID: 26632531 [TBL] [Abstract][Full Text] [Related]
2. Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation. Mabuchi H; Nohara A; Noguchi T; Kobayashi J; Kawashiri MA; Inoue T; Mori M; Tada H; Nakanishi C; Yagi K; Yamagishi M; Ueda K; Takegoshi T; Miyamoto S; Inazu A; Koizumi J; Atherosclerosis; 2014 Sep; 236(1):54-61. PubMed ID: 25014035 [TBL] [Abstract][Full Text] [Related]
3. The contribution of PCSK9 levels to the phenotypic severity of familial hypercholesterolemia is independent of LDL receptor genotype. Drouin-Chartier JP; Tremblay AJ; Hogue JC; Ooi TC; Lamarche B; Couture P Metabolism; 2015 Nov; 64(11):1541-7. PubMed ID: 26371983 [TBL] [Abstract][Full Text] [Related]
4. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects. Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287 [TBL] [Abstract][Full Text] [Related]
5. Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia. Grenkowitz T; Kassner U; Wühle-Demuth M; Salewsky B; Rosada A; Zemojtel T; Hopfenmüller W; Isermann B; Borucki K; Heigl F; Laufs U; Wagner S; Kleber ME; Binner P; März W; Steinhagen-Thiessen E; Demuth I Atherosclerosis; 2016 Oct; 253():88-93. PubMed ID: 27596133 [TBL] [Abstract][Full Text] [Related]
6. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways. Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370 [TBL] [Abstract][Full Text] [Related]
7. Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes. Strøm TB; Holla ØL; Cameron J; Berge KE; Leren TP Clin Chim Acta; 2010 Feb; 411(3-4):229-33. PubMed ID: 19917273 [TBL] [Abstract][Full Text] [Related]
8. Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients. Slimani A; Jelassi A; Jguirim I; Najah M; Rebhi L; Omezzine A; Maatouk F; Hamda KB; Kacem M; Rabès JP; Abifadel M; Boileau C; Rouis M; Slimane MN; Varret M Atherosclerosis; 2012 May; 222(1):158-66. PubMed ID: 22417841 [TBL] [Abstract][Full Text] [Related]
9. Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia. Ohta N; Hori M; Takahashi A; Ogura M; Makino H; Tamanaha T; Fujiyama H; Miyamoto Y; Harada-Shiba M J Clin Lipidol; 2016; 10(3):547-555.e5. PubMed ID: 27206942 [TBL] [Abstract][Full Text] [Related]
10. Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia. Pisciotta L; Sallo R; Rabacchi C; Wunsch A; Calandra S; Bertolini S Nutr Metab Cardiovasc Dis; 2012 Oct; 22(10):831-5. PubMed ID: 21920719 [TBL] [Abstract][Full Text] [Related]
11. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study. Saavedra YG; Dufour R; Davignon J; Baass A Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291 [TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia. Abifadel M; Guerin M; Benjannet S; Rabès JP; Le Goff W; Julia Z; Hamelin J; Carreau V; Varret M; Bruckert E; Tosolini L; Meilhac O; Couvert P; Bonnefont-Rousselot D; Chapman J; Carrié A; Michel JB; Prat A; Seidah NG; Boileau C Atherosclerosis; 2012 Aug; 223(2):394-400. PubMed ID: 22683120 [TBL] [Abstract][Full Text] [Related]
13. A novel type of familial hypercholesterolemia: double heterozygous mutations in LDL receptor and LDL receptor adaptor protein 1 gene. Tada H; Kawashiri MA; Ohtani R; Noguchi T; Nakanishi C; Konno T; Hayashi K; Nohara A; Inazu A; Kobayashi J; Mabuchi H; Yamagishi M Atherosclerosis; 2011 Dec; 219(2):663-6. PubMed ID: 21872251 [TBL] [Abstract][Full Text] [Related]
14. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. Urban D; Pöss J; Böhm M; Laufs U J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703 [TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia. Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088 [TBL] [Abstract][Full Text] [Related]
17. Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children. Girona J; Rodríguez-Borjabad C; Ibarretxe D; Heras M; Amigo N; Feliu A; Masana L; Plana N; J Clin Lipidol; 2018; 12(1):211-218. PubMed ID: 29102496 [TBL] [Abstract][Full Text] [Related]
18. Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study. Sun D; Li S; Zhao X; Wu NQ; Zhu CG; Guo YL; Gao Y; Qing P; Cui CJ; Liu G; Sun J; Dong Q; Li JJ Metabolism; 2018 Feb; 79():33-41. PubMed ID: 29129821 [TBL] [Abstract][Full Text] [Related]
19. A novel mutation in proprotein convertase subtilisin/kexin type 9 gene leads to familial hypercholesterolemia in a Chinese family. Lin J; Wang LY; Liu S; Wang XM; Yong Q; Yang Y; DU LP; Pan XD; Wang X; Jiang ZS Chin Med J (Engl); 2010 May; 123(9):1133-8. PubMed ID: 20529551 [TBL] [Abstract][Full Text] [Related]
20. Clinical features of familial hypercholesterolemia in Korea: Predictors of pathogenic mutations and coronary artery disease - A study supported by the Korean Society of Lipidology and Atherosclerosis. Shin DG; Han SM; Kim DI; Rhee MY; Lee BK; Ahn YK; Cho BR; Woo JT; Hur SH; Jeong JO; Jang Y; Lee JH; Lee SH Atherosclerosis; 2015 Nov; 243(1):53-8. PubMed ID: 26343872 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]